ATE502016T1 - Triazolo-ä1,5-aü-chinoline als adenosin-a3- rezeptorliganden - Google Patents

Triazolo-ä1,5-aü-chinoline als adenosin-a3- rezeptorliganden

Info

Publication number
ATE502016T1
ATE502016T1 AT08762666T AT08762666T ATE502016T1 AT E502016 T1 ATE502016 T1 AT E502016T1 AT 08762666 T AT08762666 T AT 08762666T AT 08762666 T AT08762666 T AT 08762666T AT E502016 T1 ATE502016 T1 AT E502016T1
Authority
AT
Austria
Prior art keywords
quinolines
triazolo
adenosine
receptor ligands
ligands
Prior art date
Application number
AT08762666T
Other languages
English (en)
Inventor
N Edit Sus
Kinga Boer
Zoltan Kapui
Ri Geza Tim
Tori Sandor B
Vik Zoltan Szl
Endre Mikus
Ne Szeredi Judit Varg
Michel Finet
N Szaba Katalin Urb
Tibor Szaba
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE502016T1 publication Critical patent/ATE502016T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
AT08762666T 2007-06-07 2008-06-02 Triazolo-ä1,5-aü-chinoline als adenosin-a3- rezeptorliganden ATE502016T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0700395A HUP0700395A2 (en) 2007-06-07 2007-06-07 Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
PCT/HU2008/000063 WO2008149168A1 (en) 2007-06-07 2008-06-02 Triazolo [1, 5-a] quinolines as adenosine a3 receptor ligands

Publications (1)

Publication Number Publication Date
ATE502016T1 true ATE502016T1 (de) 2011-04-15

Family

ID=89987565

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08762666T ATE502016T1 (de) 2007-06-07 2008-06-02 Triazolo-ä1,5-aü-chinoline als adenosin-a3- rezeptorliganden

Country Status (44)

Country Link
US (1) US8338411B2 (de)
EP (1) EP2167470B1 (de)
JP (1) JP5487100B2 (de)
KR (1) KR20100031610A (de)
CN (1) CN101679272B (de)
AR (1) AR066873A1 (de)
AT (1) ATE502016T1 (de)
AU (1) AU2008259534B2 (de)
BR (1) BRPI0812257A2 (de)
CA (1) CA2689612A1 (de)
CL (1) CL2008001648A1 (de)
CO (1) CO6270233A2 (de)
CR (1) CR11171A (de)
CY (1) CY1111644T1 (de)
DE (1) DE602008005589D1 (de)
DK (1) DK2167470T3 (de)
DO (1) DOP2009000276A (de)
EC (1) ECSP099783A (de)
ES (1) ES2363672T3 (de)
GT (1) GT200900301A (de)
HN (1) HN2009003357A (de)
HR (1) HRP20110332T1 (de)
HU (1) HUP0700395A2 (de)
IL (1) IL202471A0 (de)
JO (1) JO2689B1 (de)
MA (1) MA31738B1 (de)
ME (1) ME00958B (de)
MX (1) MX2009013209A (de)
MY (1) MY148654A (de)
NI (1) NI200900210A (de)
NZ (1) NZ581186A (de)
PA (1) PA8782901A1 (de)
PE (1) PE20090325A1 (de)
PL (1) PL2167470T3 (de)
PT (1) PT2167470E (de)
RU (1) RU2489432C2 (de)
SI (1) SI2167470T1 (de)
SV (1) SV2009003420A (de)
TN (1) TN2009000482A1 (de)
TW (1) TWI424998B (de)
UA (1) UA99463C2 (de)
UY (1) UY31130A1 (de)
WO (1) WO2008149168A1 (de)
ZA (1) ZA200908280B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176983A1 (en) 2009-07-08 2012-02-28 Dermira Canada Inc Tofa analogs useful in treating dermatological disorders or conditions
FR3053968A1 (fr) * 2016-07-13 2018-01-19 Biomerieux Reactifs pour la protection reversible de molecules biologiques
MA45202B1 (fr) * 2016-09-24 2022-04-29 Kbp Biosciences Co Ltd Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation
MA52422A (fr) 2018-02-27 2021-01-06 Incyte Corp Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
MA53097A (fr) 2018-07-05 2021-05-12 Incyte Corp Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b
CR20210271A (es) 2018-11-30 2021-07-14 Merck Sharp & Dohme Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso
MA54551A (fr) 2018-12-20 2021-10-27 Incyte Corp Composés d'imidazopyridazine et d'imidazopyridine utilisés en tant qu'inhibiteurs de la kinase 2 de type récepteur de l'activine
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479759A (en) * 1974-11-23 1977-07-13 Lepetit Spa Heterocyclic fused derivatives of indole and quinoline
GR76063B (de) * 1981-04-03 1984-08-03 Roussel Uclaf
ZA836701B (en) * 1982-10-01 1984-10-31 Roussel Uclaf Imidazo(1,2-a)quinolines
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
EA006854B1 (ru) * 2001-05-31 2006-04-28 Санофи-Авентис Производные аминохинолина и его применение в качестве лигандов аденозина a
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
HUP0105406A3 (en) * 2001-12-21 2003-12-29 Sanofi Aventis Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
WO2003053973A1 (de) 2001-12-21 2003-07-03 Jsw-Research Forschungslabor Gmbh Pyrazolyl-substituierte triazolochinoxaline
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
MEP19108A (en) * 2003-07-31 2010-06-10 Sanofi Aventis Aminoquinoline derivatives and their use as adenosine a3 ligands

Also Published As

Publication number Publication date
CN101679272A (zh) 2010-03-24
PL2167470T3 (pl) 2011-08-31
ME00958B (me) 2012-06-20
RU2489432C2 (ru) 2013-08-10
AR066873A1 (es) 2009-09-16
TWI424998B (zh) 2014-02-01
WO2008149168A1 (en) 2008-12-11
CR11171A (es) 2010-04-21
SV2009003420A (es) 2010-04-26
AU2008259534A1 (en) 2008-12-11
SI2167470T1 (sl) 2011-06-30
CO6270233A2 (es) 2011-04-20
IL202471A0 (en) 2010-06-30
HK1138581A1 (en) 2010-08-27
HU0700395D0 (en) 2007-07-30
CA2689612A1 (en) 2008-12-11
MA31738B1 (fr) 2010-10-01
GT200900301A (es) 2010-04-22
HUP0700395A2 (en) 2009-03-02
PA8782901A1 (es) 2009-01-23
TN2009000482A1 (en) 2011-03-31
ZA200908280B (en) 2010-07-28
HRP20110332T1 (hr) 2011-06-30
ES2363672T3 (es) 2011-08-11
MX2009013209A (es) 2010-04-09
NZ581186A (en) 2012-03-30
EP2167470A1 (de) 2010-03-31
US8338411B2 (en) 2012-12-25
RU2009149518A (ru) 2011-07-20
CN101679272B (zh) 2013-02-06
DOP2009000276A (es) 2010-01-31
JO2689B1 (en) 2013-03-03
US20100216786A1 (en) 2010-08-26
CL2008001648A1 (es) 2008-10-10
NI200900210A (es) 2010-07-15
ECSP099783A (es) 2010-01-29
PT2167470E (pt) 2011-05-16
DK2167470T3 (da) 2011-06-27
JP5487100B2 (ja) 2014-05-07
DE602008005589D1 (de) 2011-04-28
JP2010529100A (ja) 2010-08-26
MY148654A (en) 2013-05-15
PE20090325A1 (es) 2009-04-17
KR20100031610A (ko) 2010-03-23
AU2008259534B2 (en) 2012-07-05
WO2008149168A8 (en) 2010-01-07
UA99463C2 (en) 2012-08-27
UY31130A1 (es) 2009-01-30
HN2009003357A (es) 2013-08-12
EP2167470B1 (de) 2011-03-16
CY1111644T1 (el) 2015-10-07
TW200914451A (en) 2009-04-01
BRPI0812257A2 (pt) 2014-12-23

Similar Documents

Publication Publication Date Title
HRP20151058T1 (xx) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
NO2021006I1 (no) Quofenix, delafloksacin
CL2007002263S1 (es) Motoneta.
BRPI0815717A2 (pt) Compostos de imidazopirazina.
ATE513831T1 (de) Pyridinä3,4-büpyrazinone
IS8842A (is) Kjarnviðtaka bindimiðlar.
EP2155602A4 (de) Boronnitrid-nanoröhrchen
CL2008000457S1 (es) Motoneta.
BRPI0919135A2 (pt) compostos inéditos como ligantes do receptor canabinóide.
CL2007003097S1 (es) Motocicleta.
EP2344471A4 (de) 7-piperidinalkyl-3,4-dihydrochinolon-derivat
BRPI0810926A2 (pt) Antagonista de crig
BRPI0820805A2 (pt) Antagonista do receptor de mineralocorticóides derivados da 6h-di-benzo[b,e]oxepina
ATE527260T1 (de) (dihydro)pyrroloä2,1-aüisoquinoline
ATE502016T1 (de) Triazolo-ä1,5-aü-chinoline als adenosin-a3- rezeptorliganden
ATE518843T1 (de) Pyrimidinyl-piperazine als dopamin d3/d2- rezeptorliganden
BRPI0816679A2 (pt) Derivados de ftalazinona.
DE602008003432D1 (de) Substituierte furoä2,3-büpyridinderivate als cannabinoid-1-rezeptormodulatoren
ATE519751T1 (de) Dihydro-benzoäbüä1,4üdiazepin-2-on- sulfonamidderivate
ITTO20080751A1 (it) Motociclo.
NL2002217A1 (nl) Mat.
FI20071026A0 (fi) Vihko-/monistetasku
CL2007003307S1 (es) Motocicleta.
CL2007003338S1 (es) Motocicleta.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2167470

Country of ref document: EP